Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. engages in the research and development, manufacture, and sale of packaging materials for the pharmaceuticals' industry in China and internationally. It offers covered rubber stoppers serise; halogenated butyl rubber stopper freeze-dryied series; halogenated butyl rubber stopper antibiotics series; halogenated butyl rubber plugs infusion series;… Read more
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (301093) - Net Assets
Latest net assets as of June 2025: CN¥2.27 Billion CNY
Based on the latest financial reports, Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (301093) has net assets worth CN¥2.27 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.52 Billion) and total liabilities (CN¥256.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.27 Billion |
| % of Total Assets | 89.84% |
| Annual Growth Rate | 44.19% |
| 5-Year Change | 467.31% |
| 10-Year Change | N/A |
| Growth Volatility | 203.61 |
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (2019–2024)
The table below shows the annual net assets of Jiangsu Hualan New Pharmaceutical Material Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.25 Billion | -9.55% |
| 2023-12-31 | CN¥2.49 Billion | +2.91% |
| 2022-12-31 | CN¥2.42 Billion | -0.02% |
| 2021-12-31 | CN¥2.42 Billion | +509.61% |
| 2020-12-31 | CN¥396.39 Million | +9.96% |
| 2019-12-31 | CN¥360.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 186.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥423.86 Million | 18.87% |
| Other Components | CN¥1.82 Billion | 81.13% |
| Total Equity | CN¥2.25 Billion | 100.00% |
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. Competitors by Market Cap
The table below lists competitors of Jiangsu Hualan New Pharmaceutical Material Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Narayana Hrudayalaya Ltd.
NSE:NH
|
$1.26 Billion |
|
SKC Co. Ltd
KO:011790
|
$1.26 Billion |
|
FAIRFAX INDIA HLDGS
F:F5X
|
$1.26 Billion |
|
DEME Group NV
BR:DEME
|
$1.26 Billion |
|
Primaris Real Estate Investment Trust
PINK:PMREF
|
$1.26 Billion |
|
YGSOFT Inc
SHE:002063
|
$1.26 Billion |
|
Stadler Rail AG
PINK:SRAIF
|
$1.26 Billion |
|
Gemalto N.V
OTCGREY:GTOFF
|
$1.26 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,486,173,137 to 2,245,764,811, a change of -240,408,326 (-9.7%).
- Net income of 49,573,270 contributed positively to equity growth.
- Dividend payments of 77,654,380 reduced retained earnings.
- Other factors decreased equity by 212,327,217.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥49.57 Million | +2.21% |
| Dividends Paid | CN¥77.65 Million | -3.46% |
| Other Changes | CN¥-212.33 Million | -9.45% |
| Total Change | CN¥- | -9.67% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23.68x to 4.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.57 | CN¥84.50 | x |
| 2020-12-31 | CN¥3.92 | CN¥84.50 | x |
| 2021-12-31 | CN¥13.80 | CN¥84.50 | x |
| 2022-12-31 | CN¥13.80 | CN¥84.50 | x |
| 2023-12-31 | CN¥14.08 | CN¥84.50 | x |
| 2024-12-31 | CN¥17.67 | CN¥84.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Hualan New Pharmaceutical Material Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.45%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.12x
- Recent ROE (2.21%) is below the historical average (11.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 26.40% | 20.70% | 0.77x | 1.66x | CN¥59.13 Million |
| 2020 | 20.52% | 18.23% | 0.72x | 1.57x | CN¥41.72 Million |
| 2021 | 8.94% | 26.32% | 0.31x | 1.09x | CN¥-25.63 Million |
| 2022 | 3.88% | 16.05% | 0.23x | 1.07x | CN¥-147.84 Million |
| 2023 | 4.74% | 18.93% | 0.23x | 1.09x | CN¥-130.69 Million |
| 2024 | 2.21% | 8.45% | 0.23x | 1.12x | CN¥-175.00 Million |
Industry Comparison
This section compares Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,246,530,775
- Average return on equity (ROE) among peers: 12.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (301093) | CN¥2.27 Billion | 26.40% | 0.11x | $1.26 Billion |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $763.05 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.12 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $346.13 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $234.74 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $784.88 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $545.42 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.41 Billion | 16.14% | 0.58x | $438.45 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.55 Billion | 13.64% | 0.15x | $1.62 Billion |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |